Clinical Research Directory

Inclusion Criteria: 1. Willing to sign informed consent form. If the patient is under 18 years of age, the parent or legally acceptable representative of the child/adolescent who can participate in this study also signs the consent form. 2. Diagnosis of primary C3G or IC-MPGN confirmed by the results of morphological and clinical studies. 3. The results of serum creatinine level, proteinuria determination obtained not earlier than 4 weeks before the kidney biopsy 4. Index date (kidney biopsy) not earlier than March 2024 and not later than 11 months before signing the ICF 5. The estimated baseline GFR (using the CKD-EPI formula for persons aged over 18 years and the modified Schwarz formula for children) or the measured GFR is ≥30 mL/min per 1.73 m2. Exclusion Criteria: 1. Patients participating in a clinical trial with the investigational product. 2. Patients with monoclonal gammopathies (myeloma, B-cell lymphoma/lymphocytic leukemia, lymphoplasmacytoma) 3. Patients with systemic autoimmune diseases and vasculitis (systemic lupus erythematosus, systemic sclerosis, dermatomyositis, mixed connective tissue disease, Sjogren syndrome, Henoch-Schönlein purpura, ANCA vasculitis, cryoglobulinemia) 4. Patients with current or recent infections (viral hepatitis B, viral hepatitis C, infective endocarditis or sepsis, infected ventriculoatrial shunts, abscesses, meningococcal and other bacterial infections, protozoan infections) 5. Patients with any clinically significant acute disease within 30 days prior to kidney biopsy 6. Clinically significant concomitant kidney disease 7. Treatment with pegcetacoplan Other protocol-defined inclusion/exclusion criteria may apply.